Jardiance Dosage/Direction for Use

Posology: Type 2 diabetes mellitus: The recommended starting dose is 10 mg empagliflozin once daily for monotherapy and add-on combination therapy with other glucose-lowering medicinal products. In patients tolerating empagliflozin 10 mg once daily who have an eGFR ≥30 ml/min/1.73 m² and need tighter glycaemic control, the dose can be increased to 25 mg once daily. The maximum daily dose is 25 mg (see Patients with renal impairment as follows and Precautions).
Heart failure: The recommended dose is 10 mg empagliflozin once daily.
Chronic kidney disease: The recommended dose is 10 mg empagliflozin once daily.
All indications: When empagliflozin is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia (see Interactions and Adverse Reactions).
If a dose is missed, it should be taken as soon as the patient remembers; however, a double dose should not be taken on the same day.
Special populations: Patients with renal impairment: Due to limited experience, it is not recommended to initiate treatment with empagliflozin in patients with an eGFR <20 ml/min/1.73 m².
Glycaemic efficacy of empagliflozin is dependent on renal function and likely absent in patients with severe renal impairment. If eGFR falls below 30 ml/min/1.73 m2, the recommended dose of empagliflozin is limited to 10 mg and additional glucose lowering treatment should be considered if needed (see Precautions).
Patients with hepatic impairment: No dose adjustment is required for patients with hepatic impairment. Empagliflozin exposure is increased in patients with severe hepatic impairment. Therapeutic experience in patients with severe hepatic impairment is limited and therefore not recommended for use in this population (see Pharmacology: Pharmacokinetics under Actions).
Elderly patients: No dose adjustment is recommended based on age. In patients 75 years and older, an increased risk for volume depletion should be taken into account (see Precautions and Adverse Reactions).
Paediatric population: Type 2 diabetes mellitus: The recommended starting dose of Jardiance is 10 mg once daily.
In patients tolerating empagliflozin 10 mg once daily and requiring additional glycaemic control, the dose can be increased to 25 mg once daily (see general information as previously mentioned).
No data are available for children with eGFR <60 ml/min/1.73 m² and children below 10 years of age.
Heart failure: Safety and effectiveness of Jardiance for the treatment of heart failure in children under 18 years of age have not been established.
Chronic kidney disease: Safety and effectiveness of Jardiance for the treatment of CKD in children under 18 years of age have not been established.
Method of administration: The tablets can be taken with or without food, swallowed whole with water.